Advance your peptide characterisation and development

adobestock_489730860

Get to know your peptide

Growing understanding of your therapeutic peptide and its behavior can overcome analytical and formulation challenges, allowing for faster progress through clinical trials and successful delivery to patients. Peptides are prone to degradation, oxidation and other modifications posing additional analytical challenges which require sensitive and robust analytical methods for the detection and quantification of peptide-related impurities.

Expand_img

Efficient, selective, and reliable separation-driven analysis techniques are required for:

  • Peptides synthesised with natural or chemically altered amino acids
  • Modified peptides to improve biological activity, selectivity, stability and solubility
  • Complex peptide mixtures with diverse physicochemical properties
adobestock_480246380

State-of-the-art analytical capabilities

Expand_img
  • Ion-pair reversed-phase (IP-RP), ion exchange (IEX), hydrophilic interaction liquid chromatography (HILIC) and size exclusion chromatography (SEC) to separate and quantify therapeutic peptides and related degradation products
  • High-resolution mass spectrometry (HRMS) coupled to LC for supporting advanced purity/impurity and identity determination
  • Capillary electrophoresis (CE) for high resolution separation of peptide-related impurities
  • Chiral amino acid analysis (AAA) for determination of enantiomeric purity
  • Dynamic light scattering (DLS), microscopic flow imaging (MFI), and light obscuration (LO) for (subvisible) particles and aggregation studies
  • Differential scanning calorimetry (DSC) for stability assessment
  • Coulometric Karl Fisher (cKF) titration for water content determination in lyophilised peptide therapeutics
adobestock_710272736

Our integrated analytical support

Our analytical services include method development, and subsequent method qualification and validation to ICH guidelines, drug product release and stability studies

Expand_img
  • Forced degradation studies (e.g., humidity, temperature, pH, oxidation)
  • Photostability studies
  • In-use stability studies
  • ICH stability studies and testing
  • Accelerated Stability Assessment Programme (ASAP) studies for drug product prototype ranking and shelf-life predictions
adobestock_652070570

Liquid drug products

Peptide drugs are often formulated in liquid dosage forms for parenteral administration. Solubility of the peptide at the right dose as well as compatibility with the used excipients are key aspects. These aspects will be screened at the start of the project and form the fundamental base for further formulation development. Knowing the cost of the peptide drug substance, we strive to miniaturise the drug substance consumption in each step of the formulation development process.

Are you looking into formulating a cocktail of peptides? Eurofins CDMO has expertise to get your peptide mixtures in its final drug product form.

Expand_img

We can work on any of the following drug products:

  • Solution in vials or prefilled syringes for parenteral injection
  • Ophthalmic drug products like eye drop or eye injections
  • Nasal spray
  • Solution for inhalation
untitled-3

Increasing stability

Stability testing of your peptide drug product is a crucial step within the formulation development process. In cases where the stability of the peptide is challenging, other Eurofins CDMO can support. Whether it is an optimization of the formulation like adding an antioxidant, or there is need to change the dosage form, we are ready to take the lead. A freeze-dried drug product might be the solution to increase the stability of your peptide drug product.

Expand_img

To develop a freeze-dried drug product, your project can go through the following steps: 

  • Buffer and excipient screening
  • Lyophilization screening of different concepts often supported by design of experiments
  • Extensive analytical support including water content analysis
  • Short stress studies and accelerated stress studies
  • Freeze drying cycle optimization
  • Transfer to GMP scale freeze-dryer
  • Clinical production
adobestock_613766724

Clinical manufacturing

Clinical manufacturing of your developed formulation is the next step in which Eurofins CDMO can support you. Our expertise in upscaling and transfer to a GMP environment can benefit your project. Eurofins CDMO is capable of producing both sterile and non-sterile drug products with all required analytics in-house.

Expand_img
  • Forced degradation studies (e.g., humidity, temperature, pH, oxidation)
  • Photostability studies
  • In-use stability studies
  • ICH stability studies and testing
  • Accelerated Stability Assessment Program (ASAP) studies for drug product prototype ranking and shelf-life predictions

Challenging peptides and drug products

adobestock_587499903

Peptide drugs have many advantages but can be challenging in some cases

  • Does your peptide have a long peptide sequence?
  • Is your peptide a large construct of multiple sequences?
  • Has your peptide low solubility?
  • Does your peptide aggregate?

Eurofins CDMO embraces these challenges and has in-house expertise to support your peptide drug product development up to speed. 

Challenges can also lie in the drug product development rather than with the peptide properties, especially in the case for solid peptide drug products. We offer all necessary services to formulate your peptide into a tablet, mini-tablets (multiparticulates), a capsule or powder for inhalation. In case you are interested in delivering your peptide to the colon, you can find out more on our Colon targeting page.